Raymond James Upgrades PTC Therapeutics (PTCT) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
PTC Therapeutics (PTCT) PT Raised to $32 at Goldman Sachs, Reiterates Sell
May 20, 2024 2:29 PM EDTGoldman Sachs analyst Paul Choi raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $32.00 (from $18.00) while maintaining a Sell rating.
The analyst comments "The European Commission decided not to adopt and seeks a re-evaluation of the CHMP's negative opinion on Translarna;... More
PTC Therapeutics (PTCT) PT Raised to $46 at Jefferies
May 20, 2024 12:29 PM EDTJefferies analyst Kelly Shi raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $46.00 (from $35.00) while maintaining a Buy rating.
The analyst comments "We had 1x1 with mgmt after the unexpected PR of CHMP re-evaluation of Translarna. The only precedent was Glybera... More
PTC Therapeutics (PTCT) Reports EU Commission Returns Translarna Opinion to CHMP For Re-evaluation
May 20, 2024 7:01 AM EDTPTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna (ataluren) and has returned the opinion to the CHMP... More
